The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical predictors of bevacizumab-associated intestinal perforation in non-small cell lung cancer.
 
Motohiro Tamiya
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Chugai Pharma
Research Funding - Bristol-Myers Squibb; Ono Pharmaceutical
 
Hidekazu Suzuki
No Relationships to Disclose
 
Takayuki Shiroyama
No Relationships to Disclose
 
Ayako Tanaka
No Relationships to Disclose
 
Naoko Morishita
No Relationships to Disclose
 
Norio Okamoto
No Relationships to Disclose
 
Kenichi Sakai
No Relationships to Disclose
 
Hironori Shigeoka
No Relationships to Disclose
 
Kunimitsu Kawahara
No Relationships to Disclose
 
Tomonori Hirashima
Honoraria - AstraZeneca; Bayer; Boehringer Ingelheim; Chugai Pharma; Lilly Japan; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)